BofA Securities raised its one-year price target on Teva Pharmaceutical Industries (NYSE:TEVA) to $37.00 from $36.00 and left its rating unchanged at Buy, the broker said in a note cited by market reports. That revised target sits within an analyst range of $25 to $40, and the consensus recommendation across analysts similarly leans toward Buy.
The move follows what BofA characterized as a "solid" fourth-quarter update from Teva, with the bank pointing to the strength of the companys branded business and managements fiscal year 2026 guidance as reasons for greater confidence. BofA said the 2026 guidance provides increased comfort about the execution of Tevas cost efficiency program, a key element the firm expects will help mitigate the impact from the expected loss of exclusivity for the generic version of Revlimid.
Looking past the projected 2026 roll-off for generic Revlimid, BofA interpreted Tevas guidance as implying mid-single-digit adjusted revenue growth. The bank noted that Tevas branded portfolio should support sustainable revenue growth and create operating leverage, factors that underlie its maintained Buy rating and the view that the company could achieve a more growth-oriented market multiple over time.
Market data show Teva shares trading at $33.23, just beneath a 52-week high of $33.42. BofAs target increase is modest in absolute terms but reflects the brokers reception of the latest operational and financial signals from the company.
Independent analysis from InvestingPro referenced in market summaries indicates net income is expected to increase this year, while also flagging that the stock appears slightly overvalued on a Fair Value basis. Investors interested in more granular financial and operational metrics are directed to the available Pro Research Report covering Teva among a broad set of U.S. equities.
Teva also released quarterly financial results for the fourth quarter of 2025 that exceeded analysts' projections. The company reported earnings per share of $0.96, beating a consensus estimate of $0.65, and posted revenue of $4.71 billion versus an expected $4.33 billion. Those metrics underscore stronger-than-anticipated performance in the period.
Despite the earnings and revenue outperformance, Teva's shares slipped in premarket trading. Market commentary noted that analysts' forecasts had been lower, which Teva surpassed, but the immediate price reaction was negative in early trading.
Overall, the combined developments - the broker's higher target and reiterated Buy rating, the company's guidance and comments on cost efficiency, and the quarter's earnings beat - provide investors with updated signals about Teva's near-term trajectory. However, market pricing and independent Fair Value analysis suggest there remain differing views on the stock's valuation versus its operational prospects.
Data snapshot:
- New BofA price target: $37.00 (previously $36.00)
- Analyst range: $25 - $40
- Current share price: $33.23
- 52-week high: $33.42
- Q4 2025 EPS: $0.96 (vs. $0.65 expected)
- Q4 2025 Revenue: $4.71 billion (vs. $4.33 billion expected)